



210/048
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Ruth A. Gjeraset, et al.

Serial No.: 08/335,461

Filed: November 7, 1994

For: ENHANCING THE SENSITIVITY OF
TUMOR CELLS TO THERAPIES

Group Art Unit: 1804

Examiner: C. How

BOARD OF PATENT APPEALS
AND INTERFERENCES

OCT 24 2001

RECEIVED

TECH CENTER 1600/2900

OCT 23 2001

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the item identified in this Information Disclosure Statement ("IDS") is brought to the attention of the Office. The item is listed on the attached form PTO-1449 and a copy is enclosed for the convenience of the Examiner.

We direct the Examiner's attention to claim 3 of the attached patent.

The item identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicants is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicants as such.

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

☒ This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

STATEMENT UNDER 37 CFR § 1.97(e):

☐ Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

09/22/2001 CCHAU1 00000114 122475 08335461

01 FC:126 180.00 CH

☒ No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:

- ☐ A check in the amount of _____ is enclosed for the above fee(s).
☒ Please charge \$180.00 to Deposit Account No. **12-2475** for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. **12-2475**.

Dated: _____

19 October 2001

Respectfully submitted,
LYON & LYON LLP

By: _____

Scott H. Blackman
Scott H. Blackman
Reg. No. 34,088



22249

LYON & LYON LLP
633 W. Fifth Street,
Suite 4700
Los Angeles, CA
90071

210/048

08/335,461

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

APPLICANT:

Ruth A. Gjerset, et al.

FILING DATE:

November 7, 1994

GROUP:

1804

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	6,069,334	05/30/00	Jack A. Roth et al.	514	44	10/17/97
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO	
	AI							
	AJ							
	AK							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	AL	
	AM	
	AN	
	AO	
	AP	

#8055

EXAMINER:

C. Low

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant